12:00 AM
 | 
Aug 19, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Theravance sales and marketing update

Theravance relaunched Vibativ telavancin in the U.S. almost two years after distribution was placed on hold in November 2011 due to an ongoing investigation of a third-party manufacturer's production equipment and processes. The wholesale acquisition cost is $299 for a...

Read the full 186 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >